Marwan G. Fakih, MD:This is a 70-year-old female with a past medical history significant for diabetes. The patient developed rectal bleeding approximately 3 years ago. This led to further workup, including a colonoscopy. The colonoscopy showed a sigmoid tumor, and this was biopsied showing adenocarcinoma. The patient had further workup, including CT scans of the chest, abdomen, and pelvis. The CT scans showed multiple metastatic lesions in the lung and in the liver. A biopsy of one of the metastatic lesions in the liver showed an adenocarcinoma consistent with colorectal cancer. Molecular profiling confirmed that this tumor was RAS wild-type, BRAF wild-type.
The patient received FOLFIRI and cetuximab for her first-line treatment. She had an initial response followed by disease progression. The patient has an ECOG performance status of 1 now. She received FOLFOX and bevacizumab as second-line therapy. The patient developed progressive disease.
Now that the patient has progressed on first- and second-line chemotherapy, we have to consider a third-line option. The options of treatment for a patient who has progressed on irinotecan, oxaliplatin, and a fluoropyrimidine, as well as anti-EGFR therapy in the setting of a RAS wild-type tumor, is either regorafenib as monotherapy or TAS-102, which is trifluridine and tipiracil.
Our goal, at this point, is to continue to improve the overall survival of our patient. But, also important goals in the management of patients with metastatic colorectal cancer are to improve their functionality, to diminish the chances of worsening in performance status, and decrease their symptomatology.
This is an appropriate patient for TAS-102 monotherapy. The reason for such is that the patient has a good performance status, she has progressed on first- and second-line treatment, and she has no further option of cytotoxic chemotherapy. This would be an ideal candidate for TAS-102.
Case Scenario 1:
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Study Finds Susceptibility Gene Variations by Race/Ethnicity in Early-Onset CRC
February 20th 2024In an interview with Targeted Oncology, Andreana N. Holowatyj, PhD, MSCI, discussed data from a study which found racial and ethnic differences in susceptibility genes for early-onset colorectal cancer, suggesting current multigene panel tests may not be accurate for diverse populations.
Read More